Carla De Giovanni
Overview
Explore the profile of Carla De Giovanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giusti V, Ruzzi F, Landuzzi L, Ianzano M, Laranga R, Nironi E, et al.
Oncogenesis
. 2021 Nov;
10(11):77.
PMID: 34775465
HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In this work, we studied cell lines derived from two transgenic mammary tumors driven by human HER2 that showed...
2.
De Giovanni C, Landuzzi L, Palladini A, Nicoletti G, Nanni P, Lollini P
Cells
. 2021 Aug;
10(7).
PMID: 34359977
Rhabdomyosarcomas (RMS) are tumors of the skeletal muscle lineage. Two main features allow for distinction between subtypes: morphology and presence/absence of a translocation between the PAX3 (or PAX7) and FOXO1...
3.
Landuzzi L, Palladini A, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, et al.
Sci Rep
. 2021 Jan;
11(1):1563.
PMID: 33452364
We established patient-derived xenografts (PDX) from human primary breast cancers and studied whether stability or progressive events occurred during long-term in vivo passages (up to 4 years) in severely immunodeficient...
4.
De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini P, Nanni P
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31783695
The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the...
5.
De Giovanni C, Landuzzi L, Palladini A, Ianzano M, Nicoletti G, Ruzzi F, et al.
Cancers (Basel)
. 2019 Apr;
11(4).
PMID: 30979001
(1) Background: Human epidermal growth factor receptor 2 (HER2)/neu-driven carcinogenesis is delayed by preventive vaccines able to elicit autochthonous antibodies against HER2/neu. Since cooperation between different receptor tyrosine kinases (RTKs)...
6.
De Giovanni C, Nanni P, Landuzzi L, Ianzano M, Nicoletti G, Croci S, et al.
BMC Cancer
. 2019 Feb;
19(1):126.
PMID: 30732578
Background: Insulin-like Growth Factor Receptor-1 (IGF1R) system sustains the genesis of rhabdomyosarcoma through IGF2 autocrine overexpression. While several IGF1R-targeted strategies have been investigated to interphere with rhabdomyosarcoma growth, no attempt...
7.
Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, et al.
Oncoimmunology
. 2018 Sep;
7(8):e1465164.
PMID: 30221061
This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called "Triplex". Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12...
8.
Palladini A, Nicoletti G, Lamolinara A, DallOra M, Balboni T, Ianzano M, et al.
Oncotarget
. 2017 Sep;
8(33):54444-54458.
PMID: 28903354
Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in human breast cancer. We studied their interaction in hybrid transgenic mice bearing human full-length HER2 and Delta16 (F1 HER2/Delta16) in...
9.
Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, et al.
Breast Cancer Res
. 2015 May;
17:70.
PMID: 25997501
Introduction: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release of interleukin-15 (IL-15), in the...
10.
Landuzzi L, Ianzano M, Nicoletti G, Palladini A, Grosso V, Ranieri D, et al.
Oncotarget
. 2014 Nov;
5(23):11924-38.
PMID: 25426555
Homozygous knockout of p53 in mice leads to early mortality from lymphoma, with almost complete penetrance, thus hampering studies of other tumor histotypes related to p53 alterations. To avoid lymphoma...